Literature DB >> 23625979

Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.

Bernard Combe, Ronald van Vollenhoven.   

Abstract

Entities:  

Keywords:  DMARDs (biologic); Rheumatoid Arthritis; Treatment

Mesh：

Substances：

Year:  2013        PMID： 23625979     DOI： 10.1136/annrheumdis-2013-203261

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  2 in total

1.  Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.

Authors:  Jennifer Witcher; Roy Fleischmann; Vishala L Chindalore; Ryan J Hansen; Leijun Hu; David Radtke; James Voelker; Elisa Gomez; Juliet McColm
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

2.  Patients' conceptions of their own influence on good treatment response to biological therapy in chronic inflammatory arthritis.

Authors:  Ingrid Larsson
Journal:  Patient Prefer Adherence       Date:  2017-06-26       Impact factor: 2.711
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.